MA71665A - Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation - Google Patents

Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation

Info

Publication number
MA71665A
MA71665A MA71665A MA71665A MA71665A MA 71665 A MA71665 A MA 71665A MA 71665 A MA71665 A MA 71665A MA 71665 A MA71665 A MA 71665A MA 71665 A MA71665 A MA 71665A
Authority
MA
Morocco
Prior art keywords
methods
fusion proteins
transferrin receptor
receptor fusion
transferrin
Prior art date
Application number
MA71665A
Other languages
English (en)
Inventor
Gunasekaran Kannan
Junhua Wang
Annie ARGUELLO
Tina GIESE
Mihalis S. Kariolis
Cathal S. Mahon
Original Assignee
Denali Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc. filed Critical Denali Therapeutics Inc.
Publication of MA71665A publication Critical patent/MA71665A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA71665A 2021-02-11 2022-02-11 Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation MA71665A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163148543P 2021-02-11 2021-02-11
EP22753465.8A EP4291246A4 (fr) 2021-02-11 2022-02-11 Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation
PCT/US2022/016229 WO2022174114A1 (fr) 2021-02-11 2022-02-11 Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
MA71665A true MA71665A (fr) 2025-05-30

Family

ID=82837358

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71665A MA71665A (fr) 2021-02-11 2022-02-11 Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation

Country Status (6)

Country Link
US (3) US20240148866A1 (fr)
EP (1) EP4291246A4 (fr)
JP (1) JP2024507118A (fr)
CN (1) CN116997364A (fr)
MA (1) MA71665A (fr)
WO (1) WO2022174114A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025532646A (ja) * 2022-09-20 2025-10-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 膜タンパク質及びカーゴの標的内在化及び分解のための受容体介在エンドサイトーシス
AR131281A1 (es) 2022-12-05 2025-03-05 Sanofi Sa Proteínas de unión al receptor de transferrina
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002362930A2 (en) * 2001-10-16 2003-04-28 Zystor Therapeutics, Inc. Methods and compositions for targeting underglycosylated proteins across the blood brain barrier
WO2013009526A1 (fr) * 2011-07-08 2013-01-17 Merck Sharp & Dohme Corp. Procédé de purification d'une protéine de fusion fc
JP6616189B2 (ja) * 2013-12-25 2019-12-04 Ｊｃｒファーマ株式会社 血液脳関門を通過する新規抗トランスフェリン受容体抗体
CN107849555B (zh) * 2015-06-24 2022-01-04 Jcr制药股份有限公司 通过血脑屏障的抗人转铁蛋白受体抗体
CA3034589A1 (fr) * 2016-08-25 2018-03-01 Jcr Pharmaceuticals Co., Ltd. Procede de production d'une proteine de fusion d'anticorps
KR102497564B1 (ko) * 2016-12-26 2023-02-07 제이씨알 파마 가부시키가이샤 혈액뇌관문을 통과하는 신규한 항인간 트랜스페린 수용체 항체
MX2019007824A (es) * 2016-12-28 2019-09-09 Japan Chem Res Preparacion liofilizada.
PE20210347A1 (es) * 2017-10-02 2021-02-25 Denali Therapeutics Inc Proteinas de fusion que comprenden enzimas de terapia de reemplazo de enzimas
EP3898689A1 (fr) * 2018-12-20 2021-10-27 Armagen, Inc. Purification d'une protéine de fusion d'immunoglobuline iduronate-2-sulfatase

Also Published As

Publication number Publication date
US20250367284A1 (en) 2025-12-04
EP4291246A1 (fr) 2023-12-20
US20240148866A1 (en) 2024-05-09
US20250387477A1 (en) 2025-12-25
JP2024507118A (ja) 2024-02-16
CN116997364A (zh) 2023-11-03
EP4291246A4 (fr) 2024-12-11
WO2022174114A1 (fr) 2022-08-18

Similar Documents

Publication Publication Date Title
MA52390A (fr) Anticorps anti-coronavirus et procédés d'utilisation
MA71665A (fr) Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation
EP3962497A4 (fr) Compositions de protéines de fusion chimériques modifiées et leurs procédés d'utilisation
MA56074A (fr) Anticorps contre le sars-cov-2 et leurs procédés d'utilisation
MA55025A (fr) Anticorps anti-trem2 et leurs procédés d'utilisation
EP4236990A4 (fr) Variants de l'interleukine-18 et leurs procédés d'utilisation
EP3980067A4 (fr) Protéine de fusion anticorps-interleukine et procédés d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
MA51676A (fr) Protéines de fusion il-22 fc et procédés d'utilisation
MA56180A (fr) Anticorps du récepteur 1 du peptide natriurétique et procédés d'utilisation
EP3947688A4 (fr) Récepteurs de lymphocytes t et leurs procédés d'utilisation
MA54089A (fr) Anticorps anti-pd-1 humain et procédés d'utilisation associés
EP3994275A4 (fr) Sialidases humaines recombinantes, protéines de fusion de sialidases et leurs procédés d'utilisation
EP3953385A4 (fr) Anticorps cd19 et leurs procédés d'utilisation
EP3873939A4 (fr) Anticorps anti-cd79b et récepteurs d'antigènes chimériques et leurs procédés d'utilisation
EP4061847A4 (fr) Anticorps monoclonal anti-b7-h3 et ses procédés d'utilisation
EP4153618A4 (fr) Récepteurs de lymphocytes t modifiés et leurs procédés d'utilisation
EP3938400A4 (fr) Anticorps cd22 et leurs procédés d'utilisation
EP4048402A4 (fr) Lymphocytes t cytoxiques modifiés et leurs procédés d'utilisation
EP4121458A4 (fr) Protéines de type anticorps de régulation de guidage et de navigation (gnc) et leurs procédés de production et d'utilisation
MA55615A (fr) Anticorps humains qui se lient au ret et leurs procédés d'utilisation
MA53328A (fr) Anticorps anti-siglec-5 et leurs procédés d'utilisation
EP4319813A4 (fr) Multimères de peptide-mhc-immunoglobuline et leurs procédés d'utilisation
EP3947452A4 (fr) Anticorps anti-récepteur nmda et procédés d'utilisation
EP4333892A4 (fr) Récepteurs antigéniques chimériques et procédés d'utilisation